Macrogenics (mgnx) crashed 28% after pausing phase 2 tamarack study, class action accuses company of misleading investors over cancer drug trial – hagens berman

San francisco, sept. 06, 2024 (globe newswire) -- hagens berman urges macrogenics, inc. (nasdaq: mgnx) investors who suffered substantial losses to submit your losses now.

MGNX Ratings Summary

MGNX Quant Ranking